The Ad5-nCoV is one of China's eight vaccine candidates approved for
human trials at home and abroad for the respiratory disease caused
by the new coronavirus. The shot also won approval for human testing
in Canada.
China's Central Military Commission approved the use of the vaccine
by the military on June 25 for a period of one year, CanSino said in
a filing. The vaccine candidate was developed jointly by CanSino and
a research institute at the Academy of Military Science (AMS).
"The Ad5-nCoV is currently limited to military use only and its use
cannot be expanded to a broader vaccination range without the
approval of the Logistics Support Department," CanSino said,
referring to the Central Military Commission department which
approved the military use of the vaccine.
CanSino declined to disclose whether the innoculation of the vaccine
candidate is mandatory or optional, citing commercial secrets, in an
email to Reuters.
The military approval follows China's decision earlier this month to
offer two other vaccine candidates to employees at state-owned firms
travelling overseas.
[to top of second column] |
The Phase 1 and 2 clinical trials of the CanSino's vaccine candidate showed it
has the potential to prevent diseases caused by the coronavirus, which has
killed half a million people globally, but its commercial success cannot be
guaranteed, the company said.
Separately, AMS received an approval earlier this month to test its second
experimental coronavirus vaccine in humans.
No vaccine has yet been approved for commercial use against the illness caused
by the new coronavirus, but over a dozen vaccines from more than 100 candidates
globally are being tested in humans.
(Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Ana Nicolaci
da Costa)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|